Company intelligence / Profile preview
Therakind
London, England, United Kingdomtherakind.com ↗
- Ownership
- Private
- Employees
- ~11
- Development stage
- Other
01
Overview
Therakind has developed and commercialized three specialty medicines, including Jylamvo® oral methotrexate solution for paediatric and adult use in the EU/UK/US. The company’s proprietary DriDose® intranasal dry powder technology underpins its current development pipeline. Clinical results have led to marketing authorizations in Europe and the UK for several products targeting difficult-to-treat populations such as paediatric and geriatric patients.
- Therapeutic areas
- OncologyNeurologyDermatologyRheumatology
- Modalities
- Small moleculeDevicePeptidesOpioid
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Open to co-development partnerships with vaccine/pharma/distribution companies; no major named partners publicly disclosed as of June 2024.
Beyond the preview
Go deeper on Therakind.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Therakind.